secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0001558370-22-007048
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Q1 net loss $21.3M, inked Novartis deal for $54M upfront
----------------------------------------------------------------

- Q1 net loss $21.3M; collaboration revenue $0.7M (down from $6.5M YoY); cash $166.8M, runway into 2024.
- Novartis license option: $54M upfront, up to $1.5B milestones for TRACER capsids on up to 5 CNS targets.
- Alfred Sandrock appointed CEO (March 2022); Robin Swartz promoted to COO.
- TRACER AAV9 capsid yields 50-60x better brain transduction in mice/macaques vs AAV9; AAV5 capsid 20x vs AAV9.
- Preclinical data: vectorized HER2 antibody reduces tumor burden; GBA1, SOD1, anti-tau programs advancing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000155837022007048/0001558370-22-007048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000155837022007048/vygr-20220504x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-007048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer